Methods for assessing, improving, or maintaining urogenital health in postmenopausal women

Abstract

This invention relates to methods and kits useful for improving or maintaining urogenital health using an estrogen agonist/antagonist. The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. This invention also relates to methods of assessing vaginal health.

Description

FIELD OF THE INVENTION

[0002] The present invention relates to methods for improving or maintaining urogenital health using an estrogen agonist/antagonist. In postmenopausal women, conditions such as urinary and vaginal infections; incontinence; and vaginal dryness can be treated using the methods of the present invention. The present invention also relates to method of assessing vaginal health.

BACKGROUND OF THE INVENTION

[0003] Menopause occurs naturally in women at an average age of 50 to 51 years in the United States. As ovaries age, response to pituitary gonadotropins (follicle-stimulating hormone [FSH] and luteinizing hormone [LH]) decreases, initially resulting in shorter follicular phases (thus, shorter menstrual cycles), fewer ovulations, decreased progesterone production, and more irregularity in menstrual cycles. Eventually, the follicle fails to respond and does not produce estrogen. The transitional phase, during which a woman passes out of the reproductive stage, begins before menopause. It is termed the climacteric or perimenopause, although many persons refer to it as menopause.

[0004] Premature menopause refers to ovarian failure of unknown cause that occurs before age 40. It may be associated with smoking, living at high altitude, or poor nutritional status. Artificial menopause may result from oophorectomy, chemotherapy, radiation of the pelvis, or any process that impairs ovarian blood supply or ovarian function.

[0005] Symptoms of the climacteric range from nonexistent to severe. Hot flushes (flashes) and sweating secondary to vasomotor instability affect 75% of women going through the perimenopausal period. Most have hot flushes for more than 1 year, and 25 to 50% for more than 5 years. The woman feels warm or hot and may perspire, sometimes profusely. The skin, especially of the head and neck, becomes red and warm. The flush, which may last from 30 seconds to 5 minutes, may be followed by chills. Vasomotor symptoms of the hot flush coincide with the onset of LH pulses, but not every increase in LH is associated with a hot flush, suggesting that hypothalamic control of LH pulses is independent of that of flushes. This independence is confirmed by the occurrence of hot flushes in women who have had pituitary failure and do not secrete LH and/or FSH.

[0006] The large reduction in estrogen leads to profound changes in the lower genital tract; e.g., the vaginal mucosa and vulvar skin become thinner, the normal bacterial flora changes, and the labia minora, clitoris, uterus, and ovaries decrease in size. Inflammation of the vaginal mucosa (atrophic vaginitis) can cause the mucosa to have a strawberry appearance and can lead to urinary frequency and urgency, vaginal dryness, and dyspareunia. Women tend to lose pelvic muscle tone and to develop urinary incontinence, cystitis, and vaginitis.

[0007] Normal vaginal secretion is composed of vulvar secretions from sebaceous, sweat, Bartholin, and Skene glans; transudate from the vaginal wall; exfoliated vaginal and cervical cells; cervical mucous; endometrial and oviductal fluids; and microorganisms and their metabolic products. The type and amount of exfoliated cells, cervical mucous, and upper genital tract fluids are determined by the biochemical processes that are influenced by hormone levels (Huggins, G. R. and Preti, G. Clin Obstet Gynecol, 1981;24:355-377). The vaginal desquamative tissue is made up of vaginal epithelial cells that are responsive to varying amounts of estrogen and progesterone. Superficial cells, the predominant cell type in women of reproductive age, predominate when estrogen stimulation is present. Intermediate cells predominate during the luteal phase because of progestogenic stimulation. Parabasal cells predominate in the absence of either hormone, a condition that may be found in postmenopausal women who are not receiving hormone replacement therapy.

[0008] The normal vaginal flora is predominately aerobic, with an average of six different species of bacteria, the most common of which is hydrogen peroxide producing lactobacilli. The microbiology of the vagina is determined by factors that affect the ability of bacteria to survive. These factors include vaginal pH and the availability of glucose for bacterial metabolism. The premenopausal vagina is acidic, usually below a pH of 4.5. The environment is maintained by the presence of estrogen, which stimulates vaginal epithelial cells to produce glycogen, which can then be converted by lactobacilli to lactic acid. Lack of estrogenic stimulation of the vagina results in reduction in available glycogen and an increase in vaginal pH resulting in a change in vaginal flora.

[0009] Bacterial vaginosis (BV) has previously been referred to as nonspecific vaginitis or Gardnerella vaginitis. It is an alteration of normal vaginal bacterial flora that results in the loss of hydrogen peroxide-producing lactobacilli and an overgrowth of predominately anaerobic bacteria (Eschenbach, D. A., et al., J Clin Microbiol, 1989;27:251-256; Spiegel, C. A., et al., N Engl J Med, 1980;303:601-607). The most common form of vaginitis in the United States is BV. Anaerobic bacteria can be found in less than 1% of the flora of normal women. In women with BV, however, the concentration of anaerobes, as well as Gardnerella vaginatis and Mycoplasma hominis, is 100 to 1000 times higher than in normal women. Lactobacilli are usually absent.

[0010] Numerous studies have shown an association of BV with significant adverse sequelae. Women with BV have an increased risk of pelvic inflammatory disease (PID) (Eschenbach, D. A., et al., Am J Obstet Gynecol, 1988;158:819-828), postoperative cuff infections after hysterectomy (Soper, D. E. et al., Am J Obstet Gynecol, 1990;163:1016-1023), and abnormal cervical cytology (Platz-Christensen, J. J., et al., Acta Obstet Gynecol Scand, 1994;73:586-588).

[0011] Urinary tract infection in women may involve acute cystitis, recurrent cystitis, and urethritis. Women with acute cystitis generally have an abrupt onset of multiple, severe urinary tract symptoms including dysuria, frequency, and urgency associated with suprapubic or low back pain. Suprapubic tenderness may be noted on physical examination. Urinalysis reveals pyuria and sometimes hematuria. About 20% of premenopausal women with an initial episode of cystitis will have recurrent infections. More that 90% of these recurrences are caused by exogenous reinfection. Postmenopausal women may also have frequent reinfections. Hormonal replacement therapy or topically applied estrogen cream along with antimicrobial prophylaxis has been used in treating these patients. Women with dysuria caused by urethritis have a more gradual onset of mild symptoms, which may be associated with abnormal vaginal discharge or bleeding related to concurrent cervicitis. Patients may also experience lower abdominal pain. Physical examination may reveal the presence of mucopurulent cervicitis.

[0012] Vaginal dryness in postmenopausal women is presumed to be caused by vaginal atrophy due to decreased estrogenic stimulation. When estrogen levels are low or absent, vascularity of the vagina is reduced and vaginal epithelium is thinned. The decrease in vascularity and vaginal epithelium results in less transudation and vaginal moisture.

[0013] The genital and urinary tracts are intimately associated anatomically and embryologically from the earliest stages of their development. The bladder is located directly above the anterior vaginal wall and the urethra is fused to it. Both of these structures, as well as structures of the pelvic floor, are placed at risk during pregnancy and childbirth. In postmenopausal women, changes in the pelvic floor may occur due to changes in hormonal status that consequently result in incontinence, prolapse, and other disorders.

[0014] Each organ system in the pelvic floor, urinary, genital, and intestinal, traverses the pelvis and exits through its own orifice. Thus, these systems are intricately related in function and anatomic support (Wall, L. L. and DeLancey, J. O. L., Perspect Biol Med, 1991;34:486-496). Disorders of each of these components can necessarily have an impact on the functioning of the surrounding structures and the functional anatomy of the pelvic floor. The striated muscles of the pelvic floor, in combination with their fascial attachments, work together across the entire pelvis to prevent pelvic organ displacement, to maintain continence, and to control expulsive activities. Due to these complex interrelationships, each disturbance of pelvic support may be linked to problems in other organ systems. Such is the case with incontinence disorders.

[0015] The nomenclature of the pelvic muscles has been subject to debate. The levator ani muscle (the broad general term for the muscles of the pelvic floor) has been described as consisting of a diaphragmatic portion (iliococcygeus) and the more important “pubovisceral” portion (Lawson, J. O. Ann R Coll Sur Engl 1974;54:244-252). The iliococcygeus or “diaphragmatic” portion of the levator ani consists of a thin muscular sheet that arises from the pelvic sidewall on either side of the arcus tendinous and ischial spine and inserts into a midline raphe behind the rectum. The pubovisceral (“pubococcygeus”) portion of the levator ani muscle consists of a thick U-shaped band of muscle arising from the pubic bone and attaching to the lateral walls of the vagina and rectum. Therefore, the rectum is supported by a muscular sling that pulls it toward the pubic bones when the muscles contract. The muscular band is often called the puborectalis or the pubococcygeus muscle or the pubovisceral muscle. When the pubovisceral contracts, it pulls the rectum, vagina, and urethra anteriorly toward the pubic bone and constricts the lumen of these pelvic organs. It is this contractile property that is so important in maintaining urinary and fecal continence and in providing support of the genital organs (vagina, cervix, uterus) that lie upon and are supported by the levator plate.

[0016] Connective tissue is composed primarily of elastin and collagen fibers in a polysaccharide ground substance. The composition of connective tissue is not constant but varies in different sites throughout the body. Connective tissue forms capsules to help maintain the structural integrity of the organs. If connective tissue fails, muscular support will be weak. Connective tissue is not static but instead is a dynamic tissue that undergoes constant turnover and remodeling. Hormonal changes have significant effects on collagen which is thus related to aging and the postmenopausal state (Brincat, M. et al., Obstet Gynecol, 1987;70:123-127; Castelo-Branco, C. et al., Maturitas, 1992;15:113-119). Connective tissue abnormalities are a significant factor contributing to prolapse and related conditions such as urinary and fecal incontinence.

[0017] In premenopausal women, 17β-estradiol produced by the ovaries is the chief active circulating estrogen. Serum estradiol concentrations are low in preadolescent girls and increase at menarche. In women, they range from about 100 pg per milliliter (367 pmol per liter) in the follicular phase to about 600 pg per milliliter (2200 pmol per liter) at the time of ovulation. They may rise to nearly 20,000 pg per milliliter (70,000 pmol per liter) during pregnancy. After menopause, serum estradiol concentrations fall to values similar to or lower than those in men of similar age (5 to 20 pg per milliliter [18 to 74 pmol per liter]) (Yen, S. S. C. and Jaffe, R. B., eds. Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management, 3rd ed. Philadelphia: W. B. Saunders, (1991)).

[0018] The effects of estrogen on urogenital health and tone are generally positive, however, some of the non-urogenital effects of estrogen, such as increased risk of breast cancer or the occurrence of blood clots may offset its beneficial effects.

[0019] Breast cancer is typically or often a hormone-dependent disease. Women without functioning ovaries who never receive estrogen replacement rarely develop breast cancer. The female-to-male ratio for the disease is about 150 to 1. A host of findings indicate that hormones play a critical role as promoters of the disease. For most epithelial malignancies, a log-log plot of incidence versus age shows a straight-line increase with every year of life. A similar plot for breast cancer shows the same straight line increase, but with a decrease in slope beginning at the age of menopause. The three dates in a woman's life that have a major impact on breast cancer incidence are age of menarche, age at first full-term pregnancy, and age of menopause. Women who experience menarche at age 16 have only 50 to 60 percent of the lifetime breast cancer risk of women who experience menarche at age 12. Similarly, menopause occurring 10 years before the median age (52 years), whether natural or surgically induced, reduces lifetime breast cancer risk by about 35 percent. Compared with nulliparous women, women who have a first full-term pregnancy by age 18 have 30 to 40 percent the risk of breast cancer. Thus, length of menstrual life—particularly the fraction occurring before the first full-term pregnancy—is a substantial component of the total risk of breast cancer. This factor can account for 70 to 80 percent of the variation in breast cancer frequency in different countries.

[0020] International variation has provided some of the most important clues on hormonal carcinogenesis. A woman living to age 80 in North America has 1 chance in 9 of developing invasive breast cancer. Asian women have one-fifth to one-tenth the risk of breast cancer of women in North America or Western Europe. Asian women have substantially lower concentrations of estrogens and progesterone. These differences cannot be explained on a genetic basis, because Asian women living in a Western environment have a risk identical to that of their Western counterparts. These women also differ markedly in height and weight from Asian women in Asia; height and weight are critical regulators of age of menarche and have substantial effects on plasma concentrations of estrogens. (Lippman, M. E., Breast Cancer, Chapter 91, in Harrison's Principles of Internal Medicine, 14th ed., 1998).

SUMMARY OF THE INVENTION

[0021] The present invention provides methods for improving or maintaining urogenital health comprising administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

[0022] In a preferred embodiment of the methods, the patient is a postmenopausal woman.

[0023] In another preferred embodiment of the methods, the estrogen agonist/antagonist is a compound of formula (I): 1

[0024] wherein:

[0025] A is selected from CH2 and NR;

[0026] B, D and E are independently selected from CH and N;

[0027] Y is

[0028] (a) phenyl, optionally substituted with 1-3 substituents independently selected from R4;

[0029] (b) naphthyl, optionally substituted with 1-3 substituents independently selected from R4;

[0030] (c) C3-C8 cycloalkyl, optionally substituted with 1-2 substituents independently selected from R4;

[0031] (d) C3-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R4;

[0032] (e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of —O—, —NR2— and —S(O)n—, optionally substituted with 1-3 substituents independently selected from R4;

[0033] (f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of —O—, —NR2— and —S(O)n— optionally substituted with 1-3 substituents independently selected from R4; or

[0034] (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of —O—, —NR2— and —S(O)n—, optionally substituted with 1-3 substituents independently selected from R4;

[0035] Z1 is

[0036] (a) —(CH2)pW(CH2)q—;

[0037] (b) —O(CH2)pCR5R6—;

[0038] (c) —O(CH2)pW(CH2)q—;

[0039] (d) —OCHR2CHR3—; or

[0040] (e) —SCHR2CHR3—;

[0041] G is

[0042] (a) —NR7R8; 2

[0043] wherein n is 0, 1 or 2; m is 1, 2 or 3; Z2 is —NH—, —O—, —S—, or —CH2—; optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R4; or

[0044] (c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R4; or 3

[0045] Z1 and G in combination may be

[0046] W is

[0047] (a) —CH2—;

[0048] (b) —CH=CH—;

[0049] (c) —O—;

[0050] (d) —NR2—;

[0051] (e) —S(O)n—; 4

[0052] (g) —CR2(OH)—;

[0053] (h) —CONR2—;

[0054] (i) —NR2CO—; 5

[0055] (k) —C≡C—;

[0056] R is hydrogen or C1-C6 alkyl;

[0057] R2 and R3 are independently

[0058] (a) hydrogen; or

[0059] (b) C1-C4 alkyl;

[0060] R4 is

[0061] (a) hydrogen;

[0062] (b) halogen;

[0063] (c) C1-C6 alkyl;

[0064] (d) C1-C4 alkoxy;

[0065] (e) C1-C4 acyloxy;

[0066] (f) C1-C4 alkylthio;

[0067] (g) C1-C4 alkylsulfinyl;

[0068] (h) C1-C4 alkylsulfonyl;

[0069] (i) hydroxy (C1-C4)alkyl;

[0070] (j) aryl (C1-C4)alkyl;

[0071] (k) —CO2H;

[0072] (I) —CN;

[0073] (m) —CONHOR;

[0074] (n) —SO2NHR;

[0075] (o) —NH2;

[0076] (p) C1-C4 alkylamino;

[0077] (q) C1-C4 dialkylamino;

[0078] (r) —NHSO2R;

[0079] (s) —NO2;

[0080] (t) -aryl; or

[0081] (u) —OH;

[0082] R5 and R6 are independently C1-C8 alkyl or together form a C3-C10 carbocyclic ring;

[0083] R7 and R8 are independently

[0084] (a) phenyl;

[0085] (b) a C3-C10 carbocyclic ring, saturated or unsaturated;

[0086] (c) a C3-C10 heterocyclic ring containing up to two heteroatoms, selected from —O—, —N— and —S—;

[0087] (d) H;

[0088] (e) C1-C6 alkyl; or

[0089] (f) form a 3 to 8 membered nitrogen containing ring with R5 or R6;

[0090] R7 and R8 in either linear or ring form may optionally be substituted with up to three substituents independently selected from C1-C6 alkyl, halogen, alkoxy, hydroxy and carboxy;

[0091] a ring formed by R7 and R8 may be optionally fused to a phenyl ring;

[0092] e is 0, 1 or 2;

[0093] m is 1, 2 or 3;

[0094] n is 0, 1 or 2;

[0095] p is 0, 1, 2 or 3;

[0096] q is 0, 1, 2 or 3;

[0097] or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

[0098] In another preferred embodiment of the methods, the estrogen agonist/antagonist is a compound of formula (IA) 6

[0099] wherein G is 7

[0100] R4 is H, OH, F, or Cl; and B and E are independently selected from CH and N or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

[0101] In a preferred embodiment of the methods, the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

[0102] In another preferred embodiment of the methods, the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol, D-tartrate salt.

[0103] In another preferred embodiment of the methods, the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI: 89

[0104] wherein:

[0105] R1B is selected from H, OH, —O—C(O)—C1-C12 alkyl (straight chain or branched), —O—C1-C12 alkyl (straight chain or branched or cyclic), or halogens or C1-C4 halogenated ethers,

[0106] R2B, R3B, R4B, R5B, and R6B are independently selected from H, OH, —O—C(O)—C1-C12 (straight chain or branched), —O—C1-C12 (straight chain or branched or cyclic), halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl (straight chain or branched), or trifluoromethyl;

[0107] XA is selected from H, C1-C6 alkyl, cyano, nitro, trifluoromethyl, and halogen;

[0108] s is 2 or 3;

[0109] YA is the moiety: 10

[0110] wherein:

[0111] a) R7B and R8B are independently selected from the group of H, C1-C6 alkyl, or phenyl optionally substituted by CN, C1-C6 alkyl (straight chain or branched), C1-C6 alkoxy (straight chain or branched), halogen, —OH, —CF3, or —OCF3; or

[0112] b) R7B and R8B are concatenated to form a five-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NHSO2R1B, —NHCOR1B, —NO2, or phenyl optionally substituted with 1-3 (C1-C4)alkyl; or

[0113] c) R7B and R8B are concatenated to form a six-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NHSO2R1B, —NHCOR1B, —NO2, or phenyl optionally substituted with 1-3 (C1-C4)alkyl; or

[0114] d) R7B and R8B are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NHSO2R1B, —NHCOR1B—NO2, or phenyl optionally substituted with 1-3 (C1-C4)alkyl; or

[0115] e) R7B and R8B are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NHSO2R1B, —NHCOR1B, —NO2, or phenyl optionally substituted with 1-3 (C1-C4)alkyl; or

[0116] f) R7B and R8B are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B,

[0117] —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NHSO2R1B, —NHCOR1B, —NO2, or phenyl optionally substituted with 1-3 (C1-C4) alkyl;or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or

[0118] the compound, TSE-424, of formula Va below: 11

[0119] or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or

[0120] the compound EM-652 of formula III below or is EM-800 of formula IV below: 12

[0121] or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

[0122] Also provided are methods of lowering vaginal pH; treating urinary tract infections; treating vaginal dryness; treating vaginal itching; treating undesired vaginal spasms; treating vaginitis; treating vaginal yeast or bacterial infections; treating vulvar atrophy; treating cystocele, urethocele, rectocele or enterocele prolapse; treating urinary and anal incontinence; treating undesired urinary frequency or urgency; or increasing the frequency or intensity of orgasms, the methods comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

[0123] In a preferred embodiment of the methods, the patient is a postmenopausal woman.

[0124] In another preferred embodiment of the methods, the estrogen agonist/ antagonist is a compound of formula (I): 13

[0125] wherein:

[0126] A is selected from CH2 and NR;

[0127] B, D and E are independently selected from CH and N;

[0128] Y is

[0129] (a) phenyl, optionally substituted with 1-3 substituents independently selected from R4;

[0130] (b) naphthyl, optionally substituted with 1-3 substituents independently selected from R4;

[0131] (c) C3-C8 cycloalkyl, optionally substituted with 1-2 substituents independently selected from R4;

[0132] (d) C3-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R4;

[0133] (e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of —O—, —NR2— and —S(O)n—, optionally substituted with 1-3 substituents independently selected from R4;

[0134] (f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of —O—, —NR2— and —S(O)n— optionally substituted with 1-3 substituents independently selected from R4; or

[0135] (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of —O—, —NR2— and —S(O)n—, optionally substituted with 1-3 substituents independently selected from R4;

[0136] Z1 is

[0137] (a) —(CH2)pW(CH2)q—;

[0138] (b) —O(CH2)pCR5R6—;

[0139] (c) —O(CH2)pW(CH2)q—;

[0140] (d) —OCHR2CHR3—; or

[0141] (e) —SCHR2CHR3—;

[0142] G is

[0143] (a) —NR7R8; 14

[0144] wherein n is 0, 1 or 2; m is 1, 2 or 3; Z2 is —NH—, —O—, —S—, or —CH2—; optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R4; or

[0145] (c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R4; or

[0146] Z1 and G in combination may be 15

[0147] W is

[0148] (a) —CH2—;

[0149] (b) —CH═CH—;

[0150] (c) —O—;

[0151] (d) —NR2—;

[0152] (e) —S(O)n—; 16

[0153] (g) —CR2(OH)—;

[0154] (h) —CONR2—;

[0155] (i) —NR2CO—; 17

[0156] (k) —C≡C—;

[0157] R is hydrogen or C1-C6 alkyl;

[0158] R2 and R3 are independently

[0159] (a) hydrogen; or

[0160] (b) C1-C4 alkyl;

[0161] R4 is

[0162] (a) hydrogen;

[0163] (b) halogen;

[0164] (c) C1-C6 alkyl;

[0165] (d) C1-C4 alkoxy;

[0166] (e) C1-C4 acyloxy;

[0167] (f) C1-C4 alkylthio;

[0168] (g) C1-C4 alkylsulfinyl;

[0169] (h) C1-C4 alkylsulfonyl;

[0170] (i) hydroxy (C1-C4)alkyl;

[0171] (j) aryl (C1-C4)alkyl;

[0172] (k) —CO2H;

[0173] (l) —CN;

[0174] (m) —CONHOR;

[0175] (n) —SO2NHR;

[0176] (o) —NH2;

[0177] (p) C1-C4 alkylamino;

[0178] (q) C1-C4 dialkylamino;

[0179] (r) —NHSO2R;

[0180] (s) —NO2;

[0181] (t) -aryl; or

[0182] (u) —OH;

[0183] R5 and R6 are independently C1-C8 alkyl or together form a C3-C10 carbocyclic ring;

[0184] R7 and R8 are independently

[0185] (a) phenyl;

[0186] (b) a C3-C10 carbocyclic ring, saturated or unsaturated;

[0187] (c) a C3-C10 heterocyclic ring containing up to two heteroatoms, selected from —O—, —N— and —S—;

[0188] (d) H;

[0189] (e) C1-C6 alkyl; or

[0190] (f) form a 3 to 8 membered nitrogen containing ring with R5 or R6;

[0191] R7 and R8 in either linear or ring form may optionally be substituted with up to three substituents independently selected from C1-C6 alkyl, halogen, alkoxy, hydroxy and carboxy;

[0192] a ring formed by R7 and R8 may be optionally fused to a phenyl ring;

[0193] e is 0, 1 or 2;

[0194] m is 1, 2 or 3;

[0195] n is 0, 1 or 2;

[0196] p is 0, 1, 2 or 3;

[0197] q is 0, 1, 2 or 3;

[0198] or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

[0199] In another preferred embodiment of the methods, the estrogen agonist/antagonist is a compound of formula (IA) 18

[0200] R4 is H, OH, F, or Cl; and B and E are independently selected from CH and N or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

[0201] In a preferred embodiment of the methods, the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

[0202] In another preferred embodiment of the methods, the estrogen agonist/antagonist is the (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol, D-tartrate salt.

[0203] In another preferred embodiment of the methods, the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI: 19

[0204] wherein:

[0205] R1B is selected from H, OH, —O—C(O)—C1-C12 alkyl (straight chain or branched), —O—C1-C12 alkyl (straight chain or branched or cyclic), or halogens or C1-C4 halogenated ethers,

[0206] R2B, R3B, R4B, R5B, and R6B are independently selected from H, OH, —O—C(O)—C1-C12 (straight chain or branched), —O—C1-C12 (straight chain or branched or cyclic), halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl (straight chain or branched), or trifluoromethyl;

[0207] XA is selected from H, C1-C6 alkyl, cyano, nitro, trifluoromethyl, and halogen;

[0208] s is 2 or 3;

[0209] YA is the moiety: 20

[0210] wherein:

[0211] a) R7B and R8B are independently selected from the group of H, C1-C6 alkyl, or phenyl optionally substituted by CN, C1-C6 alkyl (straight chain or branched), C1-C6 alkoxy (straight chain or branched), halogen, —OH, —CF3, or —OCF3; or

[0212] b) R7B and R8B are concatenated to form a five-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NHSO2R1B, —NHCOR1B, —NO2, or phenyl optionally substituted with 1-3 (C1-C4)alkyl; or

[0213] c) R7B and R8B are concatenated to form a six-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NHSO2R1B, —NHCOR1B, —NO2, or phenyl optionally substituted with 1-3 (C1-C4)alkyl; or

[0214] d) R7B and R8B are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NHSO2R1B, —NHCOR1B—NO2, or phenyl optionally substituted with 1-3 (C1-C4)alkyl; or

[0215] e) R7B and R8B are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NHSO2R1B, —NHCOR1B, —NO2, or phenyl optionally substituted with 1-3 (C1-C4)alkyl; or

[0216] f) R7B and R8B are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NHSO2R1B, —NHCOR1B, —NO2, or phenyl optionally substituted with 1-3 (C1-C4) alkyl;or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or

[0217] the compound, TSE-424, of formula Va below: 21

[0218] or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or

[0219] the compound EM-652 of formula III below or is EM-800 of formula IV below: 22

[0220] or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

[0221] Also provided by the present invention are kits for use by a consumer to improve or maintain urogenital health comprising:

[0222] (a) a pharmaceutical composition comprising an estrogen agonist/antagonist and a pharmaceutically acceptable carrier, vehicle or diluent; and

[0223] (b) instructions describing a method of using the pharmaceutical composition to improve or maintain urogenital health; lower vaginal pH; treat urinary tract infections; treat vaginal dryness; treat vaginal itching; treat undesired vaginal spasms; treat vaginitis; treat vaginal yeast or bacterial infections; treat vulvar atrophy; treat cystocele, urethocele, rectocele or enterocele prolapse; treat urinary or anal incontinence; treat undesired urinary frequency or urgency; or increase the frequency or intensity of orgasms.

[0224] In another embodiment of the kits, an additional compound useful to improve or maintain urogenital health; lower vaginal pH; treat urinary tract infections; treat vaginal dryness; treat vaginal itching; treat undesired vaginal spasms; treat vaginitis; treat vaginal yeast or bacterial infections; treat vulvar atrophy; treat cystocele, urethocele, rectocele or enterocele prolapse; treat urinary or anal incontinence; treat undesired urinary frequency or urgency; or increase the frequency or intensity of orgasms is included in the kit.

[0225] Also provided are methods for assessing vaginal health in a patient, the methods comprising:

[0226] a) conducting a gynecological examination;

[0227] b) measuring the pH of the vagina;

[0228] c) determining the vaginal cell maturation index;

[0229] d) determining vaginal prolapse;

[0230] e) administering a questionnaire to the patient; and

[0231] f) measuring plasma hormone levels, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.

[0232] In a preferred embodiment of the methods, the gynecological examination comprises an internal evaluation of the vagina in which the condition of the vagina is characterized by indicating the condition of the vagina on a continuum using I and III below as endpoints and II as the midpoint of the continuum:

[0233] I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry;

[0234] II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or

[0235] III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length.

[0236] In another preferred embodiment of the methods, the gynecological exam further comprises an assessment of the quantity of pubic hair and the thickness of the vulva.

[0237] In another preferred embodiment of the methods, the plasma hormone levels that are measured include estradiol, luteinizing hormone, follicle-stimulating hormone, testosterone and androstenedione.

[0238] In another preferred embodiment of the methods, vaginal prolapse is determined by grading the prolapse using the following scale:

Grade 0 normal position inside the mid-vaginal axis for anterior posterior
        wall prolapse and above the ischial spines for cervical or vaginal
        cuff. By definition, the most apical point is −3 cm superior to the
        hymen.
Grade 1 if the prolapse crosses the respective thresholds and descends
        halfway to the hymen
Grade 2 decent to the hymen
Grade 3 decent 2 cm beyond the hymen
Grade 4 maximum possible descent for each site. A complete eversion is
        about 5 cm beyond hymen.

[0239] In another preferred embodiment of the methods, the questionnaire comprises questions relating to:

[0240] 1) the number of vaginal infections;

[0241] 2) the number of urinary infections;

[0242] 3) the amount of urinary leakage;

[0243] 4) the degree of vaginal dryness;

[0244] 5) the degree of vaginal itching; and

[0245] 6) a subjective assessment of overall vaginal health by the patient.

[0246] Also provided are methods for assessing vaginal health in a patient, the methods comprising:

[0247] a) conducting a gynecological examination that comprises an internal evaluation of the vagina in which the condition of the vagina is characterized by indicating the condition of the vagina on a continuum using I and III below as endpoints and II as the midpoint of the continuum:

[0248] I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry;

[0249] II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or

[0250] III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length; and assessing the quantity of pubic hair and the thickness of the vulva;

[0251] b) measuring the pH of the vagina;

[0252] c) determining the vaginal cell maturation index;

[0253] d) determining vaginal prolapse using the following scale:

Grade 0 normal position inside the mid-vaginal axis for anterior posterior
        wall prolapse and above the ischial spines for cervical or vaginal
        cuff. By definition, the most apical point is −3 cm superior to the
        hymen.
Grade 1 if the prolapse crosses the respective thresholds and descends
        halfway to the hymen
Grade 2 decent to the hymen
Grade 3 decent 2 cm beyond the hymen
Grade 4 maximum possible descent for each site. A complete eversion
        is about 5 cm beyond hymen.

[0254] e) administering a questionnaire to the patient, the questionnaire comprising questions relating to:

[0255] 1) the number of vaginal infections in a specified time period;

[0256] 2) the number of urinary infections in a specified time period;

[0257] 3) the amount of urinary leakage in a specified time period;

[0258] 4) the degree of vaginal dryness in a specified time period;

[0259] 5) the degree of vaginal itching; and

[0260] 6) a subjective assessment of overall vaginal health by the patient; and

[0261] f) measuring plasma levels of estradiol, luteinizing hormone, follicle-stimulating hormone, testosterone and androstenedione, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.

DETAILED DESCRIPTION OF THE INVENTION

[0262] The present invention relates to methods and kits for improving or maintaining urogenital health. Specifically, the invention relates to methods of lowering vaginal pH, treating urinary tract infections, treating vaginal dryness, treating vaginal itching, treating undesired vaginal spasms, treating vaginitis, treating vaginal yeast or bacterial infections, treating vulvar atrophy, treating urethrocele, cystocele, rectocele, or enterocele prolapse, treating urinary or anal incontinence, treating undesired urinary frequency or urgency, and increasing the frequency and intensity of orgasms. The present invention also relates to methods for assessing vaginal health, which are useful for determining the efficacy and safety of new pharmaceutical substances and compositions that affect the vagina and for making diagnostic decisions.

[0263] As used herein, the terms “treat”, “treatment” and “treating” include preventative (e.g., prophylactic) and palliative treatment of the disease or condition, or amelioration of a symptom of the disease or condition.

[0264] The phrase “maintaining or improving urogenital health” means the prevention of pathological urogenital conditions or symptoms of the conditions or a slowing of the processes underlying the conditions or the development of the symptoms of the conditions or a reversal of the conditions or a reversal of the symptoms of the conditions. An improvement in urogenital health may include a reduction in the urogenital infections, including vaginal and urinary infections; a reduction in vaginal dryness, itching and irritation; and/or a reduction of incontinence. An improvement in urogenital health may also include the maintenance or improvement of pelvic floor integrity, which includes prolapse.

[0265] The term “incontinence” includes urinary and anal incontinence. When the incontinence is urinary in nature, it is defined as involuntary urine loss that is a social or hygienic problem. Urinary incontinence may be stress incontinence, urge incontinence or mixed incontinence which is stress and urge incontinence occurring together, or it may be unconscious incontinence which occurs without urgency and without conscious recognition of leakage. There may be hesitancy, straining to void, poor stream as indicated by a decreased force of flow of the urinary stream. Intermittent stream may be noted as a “stop and start” pattern of urination. Or there may be incomplete emptying of the bladder or postmicurition dribble that is urine loss occurring just after normal urination has been completed.

[0266] “Anal incontinence” is the involuntary loss of feces or flatus that may be caused by rectal prolapse. Normally, the rectum is attached firmly to the levator ani muscle complex through an extensive interweaving of longitudinal muscle fibers. These attachments are important because the rectum undergoes multiple changes in position and location during the act of normal defecation. Without this attachment, the rectum would slip down through the levator muscle hiatus during defecation. In rectal prolapse, this occurs.

[0267] A “prolapse” is a downward or forward displacement of one of the pelvic organs from its normal location. Traditionally, prolapse has referred to displacement of the bladder, the uterus, or rectum. Prolapse can also relate to displacement of the vagina. These displacements have usually been graded on a scale of 0-4; the grade increases with increasing severity of the prolapse. A variety of terms are used to describe female genital prolapse that have been fixed in the literature, which terms include:

[0268] A “cystocele” is a downward displacement of the bladder.

[0269] A “cystourethocele” is a cystocele that includes the urethra as part of the prolapsing organ complex.

[0270] A “uterine prolapse” is descent of the uterus and cervix down the vaginal canal toward the vaginal introitus.

[0271] A “rectocele” is a protrusion of the rectum into the posterior vaginal lumen.

[0272] A “enterocele” is a herniation of the small bowel into the vaginal lumen.

[0273] The term “vaginitis” means inflammation of the vagina.

[0274] The phrase “undesired urinary frequency or urgency” means that a patient urinates more often than an average of a group of similar patients. Typically, this increased number of urinations makes the patient psychologically uncomfortable and is embarrassing. In addition, a patient can experience an enhanced sense of the need to urinate when compared with a similar group. This heightened sense of needing to urinate can also lead to psychological discomfort and embarrassment.

[0275] The term “increasing the frequency or intensity of orgasms” means that a patient experiences more orgasms or experiences or perceives a heightened intensity of orgasms after treatment with the present compounds than without treatment. A way to measure a patient's perception of increased number of orgasms and/or increased intensity of orgasms is to ask the patient. For example, a questionnaire can be used.

[0276] Some aspects of vaginal health status can be determined by analysis of vaginal secretions. Normal vaginal secretions are floccular in consistency, white in color, and usually located in the dependent portion of the vagina (posterior fornix). Vaginal secretions can be analyzed by a wet-mount preparation. A sample of vaginal secretions is suspended in 0.4 mL of normal saline in a glass tube, transferred to a slide, covered with a slip, and assessed by microscopy. Some clinicians prefer to prepare slides by suspending secretions in saline placed directly on the slide. Secretions should not be placed directly on the slide without saline because this method causes drying of the vaginal secretions and does not result in a well-suspended preparation. Microscopy of normal vaginal secretions reveals many superficial epithelial cells, a few white blood cells (less than one per epithelial cell), and few, if any, clue cells. Clue cells are superficial vaginal epithelial cells with adherent bacteria, usually G. vaginalis, which obliterates the crisp cell border and usually can be visualized microscopically. Potassium hydroxide 10% (KOH) may be added to the slide, or a separate preparation can be made, to examine the secretions for fungal elements. The results should be negative for women with normal vaginal microbiology. Gram stain will reveal that normal superficial epithelial cells appear normal and a predominance of gram positive rods (lactobacilli).

[0277] The phrase “adverse effects associated with estrogen” include breast tenderness, bloating, headache, increased blood clotting and menstrual bleeding in women and breast cancer. Estrogen therapy increases the risk of endometrial carcinoma. Women on long-term estrogen therapy may have an increased risk that is not reversed by concurrent administration of progestin (N Engl J Med 1995;332: 1589).

[0278] The term “postmenopausal women” is defined to include not only women of advanced age who have passed through menopause, but also women who have been hysterectomized or for some other reason have suppressed estrogen production, such as those who have undergone long-term administration of corticosteroids, suffer from Cushings' syndrome, have gonadal dysgenesis or who have undergone radiation therapy.

[0279] “Breast cancer” is defined as a malignant proliferation of epithelial cells lining the ducts or lobules of the breast.

[0280] The term “patient” means animals, particularly mammals. Preferred patients are humans, with postmenopausal female humans being the most preferred patients.

[0281] An “estrogen agonist/antagonist” is a compound that affects some of the same receptors that estrogen does, but may not affect all, and in some instances, it antagonizes or blocks estrogen. It is also known as a “selective estrogen receptor modulator” (SERM). Estrogen agonists/antagonists may also be referred to as antiestrogens although they have some estrogenic activity at some target tissues. Estrogen agonists/antagonists are therefore not what are commonly referred to as “pure antiestrogens”. Antiestrogens that can also act as agonists are referred to as Type I antiestrogens. Type I antiestrogens activate the estrogen receptor to bind tightly in the nucleus for a prolonged time but with impaired receptor replenishment (Clark, et al., Steroids, 1973;22:707, Capony et al., Mol Cell Endocrinol, 1975;3:233).

[0282] When a woman reaches menopause, changes in the urogenital system can occur. These changes include increased vaginal pH; increased number of vaginal yeast and bacterial infections, which can be exacerbated by increased vaginal pH; increased vaginal dryness and itching; undesired vaginal spasms; vaginitis; vulvar atrophy; various types of prolapse as described herein; and urinary or anal incontinence, which can be the result of a prolaspse. In accordance with the present invention, these conditions can be treated by administering an estrogen agonist/antagonist. By treating these conditions, the overall vaginal health of a patient is maintained or improved.

[0283] The estrogen agonists/antagonists of the invention may be administered systemically or locally. For systemic use, the estrogen agonists/antagonists herein are formulated for parenteral (e.g., intravenous, subcutaneous, intramuscular, intraperitoneal, intranasal or transdermal) or enteral (e.g., oral or rectal) delivery according to conventional methods. Intravenous administration can be by a series of injections or by continuous infusion over an extended period. Administration by injection or other routes of discretely spaced administration can be performed at intervals ranging from monthly, weekly to once to three or more times daily.

[0284] Preferred estrogen agonists/antagonists that can be used in the methods and kits of the present invention include the compounds described in U.S. Pat. No. 5,552,412. Those compounds are described by the formula designated herein as formula (I) given below: 23

[0285] wherein:

[0286] A is selected from CH2 and NR;

[0287] B, D and E are independently selected from CH and N;

[0288] Y is

[0289] (a) phenyl, optionally substituted with 1-3 substituents independently selected from R4;

[0290] (b) naphthyl, optionally substituted with 1-3 substituents independently selected from R4;

[0291] (c) C3-C8 cycloalkyl, optionally substituted with 1-2 substituents independently selected from R4;

[0292] (d) C3-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R4;

[0293] (e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of —O—, —NR2— and —S(O)n—, optionally substituted with 1-3 substituents independently selected from R4;

[0294] (f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of —O—, —NR2— and —S(O)n— optionally substituted with 1-3 substituents independently selected from R4; or

[0295] (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of —O—, —NR2— and —S(O)n—, optionally substituted with 1-3 substituents independently selected from R4;

[0296] Z1 is

[0297] (a) —(CH2)pW(CH2)q—;

[0298] (b) —O(CH2)pCR5R6—;

[0299] (c) —O(CH2)pW(CH2)q—;

[0300] (d) —OCHR2CHR3—; or

[0301] (e) —SCHR2CHR3—;

[0302] G is

[0303] (a) —NR7R8;

[0304] (b) 24

[0305] wherein n is 0, 1 or 2; m is 1, 2 or 3; Z2 is —NH—, —O—, —S—, or —CH2—; optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R4; or

[0306] (c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R4; or

[0307] Z1 and G in combination may be 25

[0308] W is

[0309] (a) —CH2—;

[0310] (b) —CH=CH—;

[0311] (c) —O—;

[0312] (d) —NR2—;

[0313] (e) —S(O)n—; 26

[0314] (g) —CR2(OH)—;

[0315] (h) —CONR2—;

[0316] (i) —NR2CO—; 27

[0317] (k) —C≡C—;

[0318] R is hydrogen or C1-C6 alkyl;

[0319] R2 and R3 are independently

[0320] (a) hydrogen; or

[0321] (b) C1-C4 alkyl;

[0322] R4 is

[0323] (a) hydrogen;

[0324] (b) halogen;

[0325] (c) C1-C6 alkyl;

[0326] (d) C1-C4 alkoxy;

[0327] (e) C1-C4 acyloxy;

[0328] (f) C1-C4 alkylthio;

[0329] (g) C1-C4 alkylsulfinyl;

[0330] (h) C1-C4 alkylsulfonyl;

[0331] (i) hydroxy (C1-C4)alkyl;

[0332] (j) aryl (C1-C4)alkyl;

[0333] (k) —CO2H;

[0334] (l) —CN;

[0335] (m) —CONHOR;

[0336] (n) —SO2NHR;

[0337] (o) —NH2;

[0338] (p) C1-C4 alkylamino;

[0339] (q) C1-C4 dialkylamino;

[0340] (r) —NHSO2R;

[0341] (s) —NO2;

[0342] (t) -aryl; or

[0343] (u) —OH;

[0344] R5 and R6 are independently C1-C8 alkyl or together form a C3-C10 carbocyclic ring;

[0345] R7 and R8 are independently

[0346] (a) phenyl;

[0347] (b) a C3-C10 carbocyclic ring, saturated or unsaturated;

[0348] (c) a C3-C10 heterocyclic ring containing up to two heteroatoms, selected from —O—, —N— and —S—;

[0349] (d) H;

[0350] (e) C1-C6 alkyl; or

[0351] (f) form a 3 to 8 membered nitrogen containing ring with R5 or R6;

[0352] R7 and R8 in either linear or ring form may optionally be substituted with up to three substituents independently selected from C1-C6 alkyl, halogen, alkoxy, hydroxy and carboxy;

[0353] a ring formed by R7 and R8 may be optionally fused to a phenyl ring;

[0354] e is 0, 1 or 2;

[0355] m is 1, 2 or 3;

[0356] n is 0, 1 or 2;

[0357] p is 0, 1, 2 or 3;

[0358] q is 0, 1, 2 or 3;

[0359] and optical and geometric isomers thereof; and nontoxic pharmacologically acceptable acid addition salts, N-oxides, esters, quaternary ammonium salts and prodrugs thereof.

[0360] Additional preferred compounds of the invention also disclosed in U.S. Pat. No. 5,552,412 are described by the formula designated herein as formula (IA): 28

[0361] R4 is H, OH, F, or Cl; and B and E are independently selected from CH and N, and pharmaceutically acceptable salts thereof.

[0362] Especially preferred compounds for the methods of the invention are:

[0363] cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol;

[0364] (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol;

[0365] cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol;

[0366] cis-1-[6′-pyrrolidinoethoxy-3′-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene;

[0367] 1-(4′-pyrrolidinoethoxyphenyl)-2-(4″-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline;

[0368] cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

[0369] 1-(4′-pyrrolidinoethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline; and pharmaceutically acceptable salts thereof. An especially preferred salt of (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol is the D-tartrate salt.

[0370] The syntheses of compounds of formula (I) are set forth in U.S. Pat. No. 5,552,412.

[0371] Other preferred estrogen agonists/antagonists are disclosed in U.S. Pat. No. 5,047,431. The structure of these compounds are described by the formula designated herein as formula (II) below: 29

[0372] wherein

[0373] R1A and R2A may be the same or different and are either H, methyl, ethyl or a benzyl group; and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof. A particularly preferred compound is droloxifene. The syntheses of the compounds of formula (11) are set forth in U.S. Pat. No. 5,047,431

[0374] Additional preferred estrogen agonists I antagonists are tamoxifen: (ethanamine,2-[-4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl, (Z)-2-, 2-hydroxy-1,2,3-propanetricarboxylate(1:1)) and other compounds as disclosed in U.S. Pat. No. 4,536,516; 4-hydroxy tamoxifen (i.e., tamoxifen wherein the 2-phenyl moiety has a hydroxy group at the 4 position) and other compounds as disclosed in U.S. Pat. No. 4,623,660; raloxifene: (methanone, [6-hydroxy-2-(4-hydroxyphenyl )benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride) and other compounds as disclosed in U.S. Pat. Nos. 4,418,068; 5,393,763; 5,457,117; 5,478,847 and 5,641,790; toremifene: (ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) and other compounds as disclosed in U.S. Pat. No. 4,696,949 and 4,996,225; centchroman: 1-[2-[[4-(-methoxy-2,2, dimethyl-3-phenyl-chroman-4-yl)-phenoxyl-ethyl]-pyrrolidine and other compounds as disclosed in U.S. Pat. No. 3,822,287; idoxifene: pyrrolidine, 1-[-[4-[[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl] and other compounds as disclosed in U.S. Pat. No. 4,839,155; 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol and other compounds as disclosed in U.S. Pat. No. 5,484,795; and {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone and other compounds as disclosed in published international patent application WO 95/10513.

[0375] Further preferred estrogen agonists/antagonists include EM-652 (as shown in the formula designated herein as formula (III) and EM-800 (as shown in the formula designated herein as formula (IV)). The synthesis of EM-652 and EM-800 and the activity of various enantiomers is described in Gauthier et al., J. Med. Chem., 1997;40:2117-2122. 3031

[0376] Further preferred estrogen agonists/antagonists include TSE 424 and other compounds disclosed in U.S. Pat. Nos. 5,998,402, 5,985,910, 5,780,497, 5,880,137, and European patent application EP 0802183 A1 including the compounds described by the formulae designated herein as formulae V and VI, below: 32

[0377] R1B is selected from H, OH or the C1-C12 esters (straight chain or branched) or C1-C12 (straight chain or branched or cyclic) alkyl ethers thereof, or halogens; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether;

[0378] R2B, R3B, R4B, R5B, and R6B are independently selected from H, OH or the C1-C12 esters (straight chain or branched) or C1-C12 alkyl ethers (straight chain or branched or cyclic) thereof, halogens, or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether, cyano, C1-C6 alkyl (straight chain or branched), or trifluoromethyl;

[0379] XA is selected from H, C1-C6 alkyl, cyano, nitro, trifluoromethyl, and halogen;

[0380] s is 2 or 3;

[0381] YA is selected from:

[0382] a) the moiety: 33

[0383] wherein R7B and R8B are independently selected from the group of H, C1-C6 alkyl, or phenyl optionally substituted by CN, C1-C6 alkyl (straight chain or branched), C1-C6 alkoxy (straight chain or branched), halogen, —OH, —CF3, or —OCF3;

[0384] b) a five-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of —O—, —NH—, —N(C1-C4 alkyl)-, —N═, and —S(O)u—, wherein u is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H—, —CN, —CONHR1B, —NH2, C1-C4 alkylamino, di(C1-C4)alkylamino, —NHSO2R1B, —NHCOR1B; —NO2, and phenyl optionally substituted with 1-3 (C1-C4)alkyl;

[0385] c) a six-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of —O—, —NH—, —N(C1-C4 alkyl)-, —N═, and —S(O)u—, wherein u is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B—, —NH2, C1-C4 alkylamino, di(C1-C4)alkylamino, —NHSO2R1B, —NHCOR1B, —NO2, and phenyl optionally substituted with 1-3 (C1-C4)alkyl;

[0386] d) a seven-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of —O—, —NH—, —N(C1-C4 alkyl)-, —N═, and —S(O)u—, wherein u is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B, —NH2, C1-C4 alkylamino, di(C1-C4)alkylamino, —NHSO2R1B, —NHCOR1B, —NO2, and phenyl optionally substituted with 1-3 (C1-C4)alkyl; or

[0387] e) a bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing up to two heteroatoms selected from the group consisting of —O—, —NH—, —N(C1-C4 alkyl)-, and —S(O)u—, wherein u is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONHR1B, —NH2, —N═, C1-C4 alkylamino, di(C1-C4)alkylamino, —NHSO2R1B, —NHCOR1B, —NO2, and phenyl optionally substituted with 1-3 (C1-C4) alkyl; and optical and geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.

[0388] The more preferred compounds of this invention are those having the general structures V or VI, above, wherein:

[0389] R1B is selected from H, OH or the C1-C12 esters or alkyl ethers thereof, and halogen;

[0390] R2B, R3B, R4B, R5B, and R6B are independently selected from H, OH or the C1-C12 esters or alkyl ethers thereof, halogen, cyano, C1-C6 alkyl, or trihalomethyl, preferably trifluoromethyl;

[0391] XA is selected from H, C1-C6 alkyl, cyano, nitro, trifluoromethyl, or halogen;

[0392] YA is the moiety: 34

[0393] R7B and R8B are selected independently from H, C1-C6 alkyl, or combined by —(CH2)w—, wherein w is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONH(C1-C4), —NH2, C1-C4 alkylamino, C1-C4 dialkylamino, —NHSO2(C1-C4), —NHCO(C1-C4), and —NO2; and optical and geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.

[0394] The rings formed by a concatenated R7B and R8B, mentioned above, may include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, hexamethyleneamine or heptamethyleneamine rings.

[0395] The most preferred compounds of structural formulas V and VI, above, are those wherein R1B is OH; R2B-R6B are as defined above; XA is selected from the group of Cl, NO2, CN, CF3, or CH3; YA is the moiety 35

[0396] and R7B and R8B are concatenated together as —(CH2)t—, wherein t is an integer of from 4 to 6, to form a ring optionally substituted by up to three subsituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONH(C1-C4)alkyl, —NH2, C1-C4 alkylamino, di(C1-C4)alkylamino, —NHSO2(C1-C4)alkyl, —NHCO(C1-C4)alkyl, and —NO2; and optical and geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.

[0397] In a preferred embodiment, the compound is TSE-424 as described by the formula designated herein as formula (Va) below: 36

[0398] The syntheses of compounds of formulas V, Va and VI are set forth in U.S. Pat. No. 5,998,402. The pharmaceutically acceptable salts of the estrogen agonists/antagonists of this invention may be formed of the compound itself, or of any of its esters, and include the pharmaceutically acceptable salts which are often used in pharmaceutical chemistry. For example, salts may be formed with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfonic acids including such agents as naphthalenesulfonic, methanesulfonic and toluenesulfonic acids, sulfuric acid, nitric acid, phosphoric acid, tartaric acid, pyrosulfuric acid, metaphosphoric acid, succinic acid, formic acid, phthalic acid, lactic acid and the like, most preferable with hydrochloric acid, citric acid, benzoic acid, maleic acid, acetic acid or propionic acid.

[0399] The estrogen agonists/antagonists of this invention, as discussed above, can be administered in the form of pharmaceutically acceptable salts. The salts are conveniently formed, as is usual in organic chemistry, by reacting the compound of this invention with a suitable acid, such as has been described above. The salts are quickly formed in high yields at moderate temperatures, and often are prepared by merely isolating the compound from a suitable acidic wash as the final step of the synthesis. The salt-forming acid is dissolved in an appropriate organic solvent, or aqueous organic solvent, such as an alkanol, ketone or ester. On the other hand, if the compound of this invention is desired in the free base form, it is isolated from a basic final wash step, according to the usual practice. A preferred technique for preparing hydrochlorides is to dissolve the free base in a suitable solvent and dry the solution thoroughly, as over molecular sieves, before bubbling hydrogen chloride gas through it. A preferred salt of (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol is the D-(−)-tartrate salt. It will also be recognized that it is possible to administer amorphous forms of the estrogen agonists/antagonists.

[0400] The expression “pharmaceutically acceptable salts” includes both pharmaceutically acceptable acid addition salts and pharmaceutically acceptable cationic salts. The expression “pharmaceutically-acceptable cationic salts” is intended to define but is not limited to such salts as the alkali metal salts, (e.g. sodium and potassium), alkaline earth metal salts (e.g., calcium and magnesium), aluminum salts, ammonium salts, and salts with organic amines such as benzathine (N,N′-dibenzylethylenediamine), choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), benethamine (N-benzylphenethylamine), diethylamine, piperazine, tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol) and procaine. The expression “pharmaceutically-acceptable acid addition salts” is intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, succinate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.

[0401] One of ordinary skill in the art will recognize that certain estrogen agonists/antagonists of this invention will contain one or more atoms which may be in a particular stereochemical, tautomeric, or geometric configuration, giving rise to stereoisomers, tautomers and configurational isomers. All such tautomers and isomers and mixtures thereof are included in this invention. Hydrates and solvates of the compounds of this invention are also included.

[0402] The subject invention also includes isotopically-labeled estrogen agonists/antagonists, which are structurally identical to those disclosed above, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N 18O, 17O, 31P, 32P, 35S, 18F and 36Cl, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds and of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in compound and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out known or referenced procedures and by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

[0403] Certain ester groups are preferred when a compound of this invention contains an ester. The estrogen agonists/antagonists including the compounds of formula I, IA, II, III, IV, V, Va, or VI may contain ester groups at various positions as defined herein above, where these groups are represented as —COOR9, R9 is C1-C14 alkyl, C1-C3 chloroalkyl, C1-C3 fluoroalkyl, C5-C7 cycloalkyl, phenyl, or phenyl mono- or disubstituted with C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, chloro, fluoro or tri(chloro or fluoro)methyl.

[0404] As used herein, the term “effective amount” means an amount of an estrogen agonist/antagonist or combination of estrogen agonists/antagonists that is capable of treating the described pathological condition. The specific dose of a compound or combination of compounds administered according to this invention will, of course, be determined by the particular circumstances including, for example, the compound or combination administered, the route of administration, and the severity of the pathological condition being treated.

[0405] The dose of a compound of this invention to be administered to a patient is rather widely variable and subject to the judgement of the attending physician. It should be noted that it may be necessary to adjust the dose of a compound when it is administered in the form of a salt, such as a laureate, the salt forming moiety of which has an appreciable molecular weight.

[0406] The following dosage amounts and other dosage amounts set forth elsewhere in this description and in the appendant claims are for an average human patient having a weight of about 65 kg to about 70 kg. The skilled practitioner will readily be able to determine the dosage amount required for a patient whose weight falls outside the 65 kg to 70 kg range. All doses set forth herein, and in the appendant claims, are daily doses of the free base form of the estrogen agonists/antagonists. Calculation of the dosage amount for other forms of the free base form such as salts or hydrates is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.

[0407] The general range of effective administration rates of the estrogen agonists/antagonists is from about 0.001 mg/day to about 200 mg/day. A preferred rate range is from about 0.010 mg/day to 100 mg/day. Of course, it is often practical to administer the daily dose of compound in portions, at various hours of the day. However, in any given case, the amount of compound administered will depend on such factors as the potency of the specific estrogen agonist/antagonist, the solubility of the compound, the formulation used and the route of administration. For (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol, L-tartrate salt, a preferred dosage range for humans is about 0.025 mg to about 1 mg per day. A more preferred dosage range is about 0.25 to about 0.5 mg per day.

[0408] Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 19th Edition (1995). Pharmaceutical compositions for use within the present invention can be in the form of sterile, non-pyrogenic liquid solutions or suspensions, coated capsules, suppositories, lyophilized powders, transdermal patches or other forms known in the art.

[0409] Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders.

[0410] Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidine and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.

[0411] A lubricant may be necessary in a tablet formulation to prevent the tablet and punches from sticking in the die. The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.

[0412] Tablet disintegrators are substances that facilitate the disintegration of a tablet to release a compound when the tablet becomes wet. They include starches, clays, celluloses, algins and gums, more particularly, corn and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used as well as sodium lauryl sulfate.

[0413] Tablets are often coated with sugar as a flavorant and sealant, or with film-forming protecting agents to modify the dissolution properties of the tablet. The compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established in the art.

[0414] When it is desired to administer a compound as a suppository, the typical bases may be used. Cocoa butter is a traditional suppository base, which may be modified by addition of waxes to raise its melting point slightly. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use.

[0415] The effect of the compounds may be delayed or prolonged by proper formulation. For example, a slowly soluble pellet of the compound may be prepared and incorporated in a tablet or capsule. The technique may be improved by making pellets of several different dissolution rates and filling capsules with a mixture of the pellets. Tablets or capsules may be coated with a film which resists dissolution for a predictable period of time. Topical formulations may be designed to yield delayed and/or prolonged percutaneous absorption of a compound. Even the parenteral preparations may be made long-acting, by dissolving or suspending the compound in oily or emulsified vehicles which allow it to disperse only slowly in the serum.

[0416] The term “prodrug” means a compound that is transformed in vivo to yield a compound of the present invention. The transformation may occur by various mechanisms, such as through hydrolysis in blood. A good discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A. C. S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

[0417] For example, if a compound of the present invention contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (C1-C8)alkyl, (C2-C12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C1-C2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl.

[0418] Similarly, if a compound of the present invention comprises an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (C1-C6)alkanoyloxymethyl, 1-((C1-C6)alkanoyloxy)ethyl, 1-methyl-1-((C1-C6)alkanoyloxy)ethyl, (C1-C6)alkoxycarbonyloxymethyl, N-(C1-C6)alkoxycarbonylaminomethyl, succinoyl, (C1-C6)alkanoyl, α-amino(C1-C4)alkanoyl, arylacyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, —P(O)(O(C1-C6)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).

[0419] If a compound of the present invention comprises an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as RX-carbonyl, RXO-carbonyl, NRXRX′-carbonyl where RX and RX′ are each independently (C1-C10)alkyl, (C3-C7)cycloalkyl, benzyl, or RX-carbonyl is a natural α-aminoacyl or natural α-aminoacyl-natural α-aminoacyl, —C(OH)C(O)OYX wherein YX is H, (C1-C6)alkyl or benzyl, —C(OYX0) YX1 wherein YX0 is (C1-C4) alkyl and YX1 is (C1-C6)alkyl, carboxy(C1-C6)alkyl, amino(C1-C4)alkyl or mono-N— or di-N,N—(C1-C6)alkylaminoalkyl, —C(YX2) YX3 wherein YX2 is H or methyl and YX3 is mono-N— or di-N,N—(C1-C6)alkylamino, morpholino, piperidin-1-yl or pyrrolidin-1-yl.

[0420] Advantageously, the present invention also provides kits for use by a consumer to improve or maintain urogenital health. The kits comprise a) a pharmaceutical composition comprising an estrogen agonist/antagonist and a pharmaceutically acceptable carrier, vehicle or diluent; and b) instructions describing a method of using the pharmaceutical compositions to improve or maintain urogenital health. The instructions may also indicate that the kit is to improve or maintain urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

[0421] A “kit” as used in the instant application includes a container for containing the pharmaceutical compositions and may also include divided containers such as a divided bottle or a divided foil packet. The container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a “refill” of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule. The container employed can depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle that is in turn contained within a box.

[0422] An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.

[0423] It may be desirable to provide a written memory aid, where the written memory aid is of the type containing information and/or instructions for the physician, pharmacist or patient, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested or a card which contains the same type of information. Another example of such a memory aid is a calendar printed on the card e.g., as follows “First Week, Monday, Tuesday,” . . . etc. . . . “Second Week, Monday, Tuesday, . . . ” etc. Other variations of memory aids will be readily apparent. A “daily dose” can be a single tablet or capsule or several tablets or capsules to be taken on a given day.

[0424] Another specific embodiment of a kit is a dispenser designed to dispense the daily doses one at a time. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter which indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.

[0425] It is noted that an estrogen agonist/antagonist can be used in combination with other different estrogen agonists/antagonists to maintain or improve urogenital health. In addition, estrogen agonists/antagonists can be used in combination with estrogen. Estrogen agonists/antagonists can also be used in combination with one or more additional compounds that are therapeutically useful to improve or maintain urogenital health. For example, estrogen agonists/antagonists can be used in combination with compounds that are used to treat urinary incontinence, anal incontinence, vaginal infections, urinary infections, vaginal dryness, vaginal itching, or pelvic floor integrity, including vaginal prolapse. Examples of additional compounds that can be used in combination with an estrogen agonist/antagonist include Detrol® and anti-fungal and anti-bacterial products.

[0426] An estrogen agonist/antagonist can be used in combination with a cGMP elevator agent to treat the conditions disclosed herein.

[0427] Preferred as the cGMP elevator are cGMP phosphdiesterase (PDE) inhibitors. cGMP PDE inhibitors that are selective for cGMP PDEs rather than cyclic adenosine 3′,5′-monophosphate phosphodiesterases (cAMP PDEs) and that are selective inhibitors of the cGMP PDEV isoenzyme are particularly preferred. Such particularly preferred cGMP PDE inhibitors are disclosed in U.S. Pat. Nos. 5,250,534; 5,346,901; 5,272,147; and in the international patent application WO 94/28902.

[0428] Preferred cGMP PDEV inhibitors include compounds of formula (VII): 37

[0429] wherein:

[0430] R1C is H; C1-C3 alkyl; C1-C3 perfluoroalkyl; or C3-C5 cycloalkyl;

[0431] R2C is H; C1-C6 alkyl optionally substituted with C3-C6 cycloalkyl; C1-C3 perfluoroalkyl; or C3-C6 cycloalkyl;

[0432] R3C is C1-C6 alkyl optionally substituted with C3-C6 cycloalkyl; C1-C6 perfluoroalkyl; C3-C5 cycloalkyl; C3-C6 alkenyl; or C3-C6 alkynyl;

[0433] R4C is C1-C4 alkyl optionally substituted with OH, NR5CR6C, CN, CONR5CR6C or CO2R7C; C2-C4 alkenyl optionally substituted with CN, CONR5CR6C or CO2R7C; C2-C4 alkanoyl optionally substituted with NR5CR6C; (hydroxy)C2-C4 alkyl optionally substituted with NR5CR6C; (C2-C3 alkoxy)C1-C2 alkyl optionally substituted with OH or NR5R6C; CONR5CR6C; CO2R7C; halo; NR5CR6C; NHSO2NR5CR6C; NHSO2R8C; SO2NR9CR10C or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl;

[0434] R5C and R6C are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4-N(R11C)-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or OH;

[0435] R7C is H or C1-C4 alkyl;

[0436] R8C is C1-C3 alkyl optionally substituted with NR5CR6C;

[0437] R9C and R10C together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino or 4-N(R12C)-piperazinyl group wherein said group is optionally substituted with C1-C4 alkyl, C1-C3 alkoxy, NR13CR14C or CONR13CR14C;

[0438] R11C is H; C1-C3 alkyl optionally substituted with phenyl; (hydroxy)C2-C3 alkyl; or C1-C4 alkanoyl;

[0439] R12C is H; C1-C6 alkyl; (C1-C3 alkoxy)C2-C6 alkyl; (hydroxy)C2-C6 alkyl; (R13CR14CN)C2-C6 alkyl; (R13CR14CNOC)C1-C6 alkyl; CONR13CR14C; CSNR13CR14C, or C(NH)NR13CR14C; and

[0440] R13C and R14C are each independently H; C1-C4 alkyl; (C1-C3 alkoxy)C2-C4 alkyl; or (hydroxy)C2-C4 alkyl; and

[0441] pharmaceutically acceptable salts thereof.

[0442] Preferred cGMP PDEV inhibitors include 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sufonyl]-4-methylpiperazine (sildenafil) which has the structure of formula (VIII): 38

[0443] and pharmaceutically acceptable salts thereof; the compound having the structure of formula (IX): 39

[0444] and pharmaceutically acceptable salts thereof; and the compound 3-ethyl-5-{5-[(4-ethylpiperazino)sulphonyl]-2-(2-methoxyethoxy)pyrid-3-yl}-2-(2-pyridylmethyl)-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-7-one of formula (X): 40

[0445] The compound of formula (IX) is disclosed, for example, in U.S. Pat. Nos. 5,272,147 and 5,426,107.

[0446] A preferred pharmaceutically acceptable salt of sildenafil for use in this invention is the citrate salt, and a preferred dosage range is from about 1 mg to about 100 mg.

[0447] Also preferred as cGMP PDEV inhibitors are compounds disclosed in WO 95/19978 having the formula (XI): 41

[0448] and salts and solvates thereof, in which:

[0449] R0D represents hydrogen, halogen or C1-C6alkyl,;

[0450] R1D represents hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, haloC1-C6alkyl, C3-C8cycloalkyl, C3-C8cycloalkylC1-C3alkyl, arylC1-C3alkyl or heteroarylC1-C3alkyl;

[0451] R2D represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring 42

[0452] attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3D represents hydrogen or C1-C3alkyl, or R1D and R3D together represent a 3- or 4-membered alkyl or alkenyl ring.

[0453] A preferred group of compounds having formula XIa (also disclosed in WO 95/19978) includes compounds of the formula: 43

[0454] and salts and solvates thereof, in which:

[0455] R0D represents hydrogen, halogen or C1-C6alkyl;

[0456] R1D represents hydrogen, C1-C6alkyl, haloC1-C6alkyl, C3-C8cycloalkyl, C3-C8cycloalkyl-C1-C3alkyl, arylC1-C3alkyl or heteroarylC1-C3alkyl; and

[0457] R2D represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring 44

[0458] attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen.

[0459] cGMP elevators of the present invention include produgs, geometric isomers, stereoisomers, hydrates, tautomers and salts of the described compounds.

[0460] Suitable cGMP PDE inhibitors also include those disclosed in the following US patents:

[0461] a 5-substituted pyrazolo[4,3-d]pyrimidine-7-one disclosed in U.S. Pat. No. 4,666,908;

[0462] a griseolic acid derivative disclosed in any of U.S. Pat. Nos. 4,634,706, 4,783,532, 5,498,819, 5,532,369, 5,556,975, and 5,616,600;

[0463] a 2-phenylpurinone derivative disclosed in U.S. Pat. No. 4,885,301;

[0464] a phenylpyridone derivative disclosed in U.S. Pat. No. 5,254,571;

[0465] a fused pyrimidine derivative disclosed in U.S. Pat. No. 5,047,404;

[0466] a condensed pyrimidine derivative disclosed in U.S. Pat. No. 5,075,310;

[0467] a pyrimidopyrimidine derivative disclosed in U.S. Pat. No. 5,162,316;

[0468] a purine compound disclosed in U.S. Pat. No. 5,073,559;

[0469] a quinazoline derivative disclosed in U.S. Pat. No. 5,147,875;

[0470] a phenylpyrimidone derivative disclosed in U.S. Pat. No. 5,118,686;

[0471] an imidazoquinoxalinone derivative or its aza analog disclosed in U.S. Pat. Nos. 5,055,465 and 5,166,344;

[0472] a phenylpyrimidone derivative disclosed in U.S. Pat. No. 5,290,933;

[0473] a 4-aminoquinazoline derivative disclosed in U.S. Pat. Nos. 5,436,233 or 5,439,895;

[0474] a 4,5-dihydro-4-oxo-pyrrolo[1,2-a]quinoxaline derivative disclosed in U.S. Pat. No. 5,405,847;

[0475] a polycyclic guanine derivative disclosed in U.S. Pat. No. 5,393,755;

[0476] a nitogenous heterocyclic compound disclosed in U.S. Pat. No. 5,576,322;

[0477] a quinazoline derivative disclosed in U.S. Pat. No. 4,060,615;

[0478] a 6-heterocyclyl pyrazolo[3,4-d]pyrimidin-4-one disclosed in U.S. Pat. No. 5,294,612; and

[0479] a 4-aminoquinazoline derivative disclosed in U.S. Pat. No. 5,436,233;

[0480] Other disclosures of cGMP PDE inhibitors include:

[0481] European patent application (EPA) publication no. 0428268;

[0482] European patent 0442204;

[0483] International patent application publication no. WO 94/19351;

[0484] Japanese patent application 5-222000;

[0485] European Journal of Pharmacology, 251, (1994), 1;

[0486] International patent application publication no. WO 94/22855;

[0487] a pyrazolopyrimidine derivative disclosed in European patent application 0636626;

[0488] a 4-aminopyrimidine derivative disclosed in European patent application 0640599;

[0489] an imidazoquinazoline derivative disclosed in International patent application WO95/06648;

[0490] an anthranilic acid derivative disclosed in International patent application WO95/18097;

[0491] a tetracyclic derivative disclosed in International patent application WO95/19978;

[0492] an imidazoquinazoline derivative as disclosed in European patent application 0668280; and

[0493] a quinazoline compound disclosed in European patent application 0669324.

[0494] The cGMP PDE inhibition of a compound can be determined by standard assays known to the art, for example as disclosed in U.S. Pat. No. 5,250,534. Compounds that are selective inhibitors of cGMP PDE relative to cAMP PDE are preferred, and determination of such compounds is also taught in U.S. Pat. No. 5,250,534. Particularly preferred are compounds that selectively inhibit the PDEv isoenzyme, as disclosed in WO 94/28902.

[0495] In addition, an estrogen agonist/antagonist can be used in combination with antibiotics such as azithromycin.

[0496] The additional compounds that can be administered with an estrogen agonist/antagonist can be administered in the same dosage form or in different dosage forms. Likewise, the additional compounds can be administered at the same time as the estrogen agonist/antagonist or at different times. All combinations of dosage form and times are contemplated.

[0497] It is also noted that an estrogen agonist/antagonist can be administered using a topical dosage form such as a patch that is placed on the skin or an ointment that is rubbed on the skin. Such a dosage form can be used to administer other compounds that can be used in combination with an estrogen agonist/antagonist. In one embodiment, the estrogen agonist/antagonist is administered in combination with one or more additional compounds. In another embodiment, the additional compounds are administered using a topical dosage form and the estrogen agonist/antagonist is administered using a different dosage form such as a tablet.

[0498] The methods of measuring vaginal health involve an evaluation of vaginal health symptoms and a physical examination to determine physiological markers of vaginal health. The methods may also include a measurement of vaginal and/or urinary tract infection frequency and/or frequency of urinary incontinence. The evaluation of pathological vaginal symptoms and subject-perceived vaginal health status is self-evaluated by the subject.

[0499] Measurements that are made during a gynecological examination include a vaginal pH measurement and a determination of vaginal maturation index. Vaginal pH measurements are performed first during an examination and always prior to vaginal maturation index measurement or a PAP smear. If, at the beginning of the examination, a significant amount of lubricant is required to insert the speculum, the pH may be measured prior to the insertion of the speculum.

[0500] Vaginal pH measurements may be made with a single use, disposable pH probe such as the pHem-Alert™ pH probe (Imagyn Medical Technologies, Inc., Costa Mesa, Calif.). The pH probe is removed from packaging, inserted into the outer ⅓ of the vagina, and held against the lateral sidewall for about 2 seconds to moisten the paper. Contact between the pH probe and blood or cervical mucous should be avoided as the pH of these substances is generally neutral. The pH probe is then removed and immediately compared to the pH color chart accompanying the pH probe to determine the pH of the vagina.

[0501] The vaginal maturation index represents the degree of proliferation and maturation of vaginal cells. The results are reported as percentages of parabasal, intermediate, and superficial cells as determined by techniques known in the art. The vaginal maturation index smear must be taken prior to the PAP smear. A commercially available kit for cytological specimen collection may be used (PAP Pak™, Medical Packaging Corp., Camarillo, Calif.) to obtain the maturation index specimen. Generally, a rounded spatula end is used to take a gentle scraping from the mid-third lateral area of the vagina and applied to a microscope slide. The sample must not be taken from the cervix or any other area of the vagina. The sample must also be collected from a healthy area free from inflammation, infection, ulceration, debris, or other contaminants. The preparation is immediately fixed by flooding the entire slide with standard cytology fixative. The fixative may be a standard fixative for cytology specimens such as that included in the PAP Pak™ specimen collection kit. Once the fixative has dried, the specimen is evaluated microscopically and the maturation index determined.

[0502] The subject self-assessment of vaginal health is performed with a subjective vaginal health questionnaire. Typically, the questionnaire is performed in private and the results kept confidential. The questionnaire may include an envelope that is specially encoded to later identify the treatment that the subject is undergoing. Examples of the questions and the ratings for questions are shown in Table 1. An additional question may be added in subsequent questionnaires following administration of the baseline questionnaire, which question would ask: “Have you had any positive or negative vaginal changes since you have been taking the study medication?” This question may be coupled to a multiple-point ratings scale ranging from “mostly positive changes,” to “moderately positive changes,” to “mildly positive changes,” to “no changes,” to “mildly negative changes,” to “moderately negative changes,” to “mostly negative changes.”

TABLE 1
Subjective Vaginal Health Questionnaire Questions
	Question	Select Response or Report Number
1	How many children have	Natural Delivery?
	you had by:	Cesarean Section?
2	How many vaginal
	infections have you had in
	the last 6 months?
3	How many urinary tract
	infections have you had in
	the last 6 months?
4	What is the severity of any	a) No Leakage (never use protection)?
	urinary incontinence that	b) Mild Leakage (no protection
	you experience?	necessary)?
		c) Moderate Leakage (occasionally wear
		protection)?
		d) Moderately Severe Leakage
		(regularly wear protection)?
		e) Severe Leakage (must change pro-
		tection more than 2 times per day)?
5	If you experience any	a) When laughing, coughing, straining
	amount of urinary inconti-	or physically active?
	nence, when does it occur?	b) Leakage is uncontrollable and is
		preceded by a strong urge or need to
		urinate.
		c) Leakage occurs without apparent
		cause.
6	What is the number that	Scale of 1 to 7 with 1 representing no
	most closely represents	vaginal dryness and 7 representing
	your degree of vaginal	extreme vaginal dryness.
	dryness?
7	What is the number that	Scale of 1 to 7 with 1 representing no
	most closely represents	vaginal itching or irritation and 7
	your degree of vaginal	representing extreme vaginal itching or
	itching or irritation?	irritation.
8	Are you taking any pro-
	ducts to assist with vaginal
	dryness, irritation or
	itching?
9	What is your overall	No Problems.
	vaginal health.	Mild Problems.
		Moderate Problems.
		Moderately Severe Problems.
		Severe Problems.
10	What is the occurrence and	a) None
	frequency of any type of	b) Rare (less than 1 per month)
	sexual activity?	c) Infrequent (1-3 times per month)
		d) Regular (1-3 times per week)
		e) Frequent (more than 3 times per
		week)
11	What is the occurrence of	a) None
	orgasm (by any means)	b) Rare (less than 1 per month)
	with sexual activity?	c) Infrequent (1-3 times per month)
		d) Regular (1-3 times per week)
		e) Frequent (more than 3 times per
		week)
12	Has anything happened in	(e.g., change in health status or change
	your personal life to	in relationships, etc.)
	decrease your interest in
	sexual activity?

[0503] When the present assessment of vaginal health methods are used to evaluate drug efficacy or efficacy of other therapeutic methods, a vaginal health evaluation is made at the beginning of treatment. An additional evaluation is made one or more times during the course of or at the end of treatment such as every six months during the course of the study.

[0504] An important aspect of the present invention is the standardized assessment of pelvic organ prolapse and pelvic floor dysfunction. The present method can use a standardized system of terminology and grading from Baden, W. and Walter, T., Surgical Repair of Vaginal Defects, Philadelphia, J B Linnincott, 1992 and Bump, R. C. et al., The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction, Am. J. Obstet. Gynecol. 175:10-17, 1996.

[0505] Exam variables are controlled so that accurate measurements may be made over the period of observation that may range anywhere from 6 months to 2 years or more. It is important, therefore, that certain examination variables be held constant for the duration such as: (i) position of the subject during examination; (ii) type of exam table or chair; (iii) type of specula or retractors; (iv) type of straining (Valsalva maneuver or cough); (v) fullness of bladder (void prior to exam); and (vi) content of rectum (is stool present on rectal exam?).

[0506] Vaginal prolapse is graded on a 0 to 4 scale for the following types of prolapse: anterior wall urethrocele; anterior wall cystocele; superior wall uterine prolapse, posterior wall enterocele; and posterior wall rectocele. All prolapses are assigned a grade as determined in Table 2.

TABLE 2
Conditions Corresponding to Prolapse Grade
Grade   Criteria for Assigning Grade
Grade 0 Normal position inside the mid-vaginal axis for anterior posterior
        wall prolapse and above the ischial spines for cervical or vaginal
        cuff. By definition, the most apical point is −3 cm superior to the
        hymen.
Grade 1 If the prolapse crosses the respective thresholds, and descends
        halfway to the hymen.
Grade 2 Descent to the hymen.
Grade 3 Descent 2 cm beyond the hymen.
Grade 4 Maximum possible descent for each site. A complete eversion is
        −5 cm beyond the hymen.

[0507] For quantitation of pelvic organ position and prolapse, the following conditions apply: (i) the prolapse must be evaluated relative to a fixed point of reference; (ii) the ischial spines are reference for cervix or vaginal cuff prolapse; (iii) the vaginal midline axis will serve as a landmark for anterior and posterior wall prolapse; and (iv) the hymen will be the landmark for any prolapse extending beyond the ischial spines or the vaginal midline axis. The procedure for visualization of the prolapse is as follows:

[0508] (1) If an enterocele is suspected or the grade is uncertain, the examination is performed while the subject is standing.

[0509] (2) A posterior speculum blade or fingers are inserted to the vaginal apex, perineum is depressed, strain elicited, and withdrawal accomplished slowly to observe for prolapse and grade.

[0510] (3) The procedure is repeated by moving the speculum anteriorly to grade enterocele and rectocele if enterocele and rectocele are inadequately visualized in (2) above.

[0511] Finally, external urogenital measurements are made in centimeters. As the propensity of pelvic prolapse increases as the ratio of genital hiatus to perineal body measurement increases, the genital hiatus and perineal body are measured as follows:

[0512] Genital hiatus: Distance from the middle of the external meatus to the posterior mid-line hymen.

[0513] Perineal body: Distance from the posterior margin of the genital hiatus to the mid-anal opening.

[0514] During the examination for pelvic organ prolapse and pelvic floor dysfunction, objective measurements may also be made to evaluate the subject's vaginal health. These measurements may include measurements of blood estrogen and testosterone levels, measurement of vaginal pH, and measurement of the vaginal maturation index.

[0515] An internal vaginal health evaluation may be performed with continuously variable scale used under the following guidelines: The examiner is presented with a printed line of between 3 and 20 centimeters in length, preferably between 6 and 15 centimeters in length and most preferably 10 centimeters in length. The line is scaled with axis markers corresponding to degrees of internal vaginal health. For example, on a horizontal line, 10 centimeters in length, one end of the line may be marked with the numeral (I), the midpoint of the line marked with the numeral (II) and the end of the line opposite of numeral (I) is marked with the numeral (III). The numerals I-III are indicated to correspond to the following condition:

[0516] (I) No rugae, elasticity non-existent, friable and bleeds to the touch, mucosa very pale, very dry, stenotic, narrow vaginal apex.

[0517] (II) Few rugae, mild elasticity, mucosa pale in color (not pink), loss of some moisture, slightly stenotic, mild narrowing of vaginal apex.

[0518] (III) Rugae present, good elasticity, pink, roboust mucosa, good vaginal moisture, normal vaginal apex with good depth.

[0519] The examiner is instructed to place a mark on the line representing the continuum of vaginal conditions from numerals I-III that best describes the internal evaluation.

[0520] In addition to the internal evaluation, an external evaluation may be obtained describing, for example, the appearance of pubic hair (i.e. very scant, scant, moderate, normal, excessive) and the condition of the labia (i.e. full thickness, mild vulvar regression, moderate vulvar regression (atrophic labia) or labial fusion (severe atrophy)).

[0521] The data obtained from the vaginal examination and tests described above are used in their totality to assess the vaginal health of a patient. The methods can be used to determine if a compound that has been administered to a patient has affected vaginal health, or the methods can be used to help a clinician assess vaginal health for the purpose of making a diagnosis. The present methods can also be used to assess changes in vaginal heath over time.

[0522] Interestingly, through the use of a self-assessment questionnaire, it has been found that postmenopausal women taking the estrogen agonist/antagonist (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol, D-tartrate salt reported an increased frequency of sexual intercourse and/or an increased number of orgasms and/or increased intensity of orgasms.

[0523] All references, and patents cited herein are incorporated by reference.

[0524] The examples set forth below are intended to illustrate specific embodiments of the present invention and are not intended to limit the scope of the specification, including the claims, in any manner.

EXAMPLES

Example 1

Improvement or Maintenance of Urogenital Health

[0525] Effects of estrogen agonists/antagonists for improving or maintaining urogenital health are assessed in a patient population of postmenopausal women not undergoing hormone replacement therapy. The efficacy of the estrogen agonist/antagonist for improving or maintaining urogenital health is measured in a random, double-blind, placebo controlled clinical study.

[0526] Patients are randomly separated into either a treatment group or a placebo group. Patients are initially given a subjective vaginal health questionnaire before receiving placebo or estrogen agonist/antagonist. Treatment or placebo is initiated and continued for 6 months. The questionnaire is administered to all patients at 3 and 6 months.

[0527] The patient self-assessment of vaginal health is performed with a subjective vaginal health questionnaire. The questionnaire is performed in private and the results kept confidential. The questionnaire is specially encoded to later identify the treatment that the patient is undergoing. Examples of the questions are given in Table 1. An additional question is added in subsequent questionnaires following the baseline questionnaire which would ask: “Have you had any positive or negative vaginal changes since you have been taking the study medication?” This question is coupled to a multiple-point ratings scale ranging from “mostly positive changes,” to “moderately positive changes,” to “mildly positive changes,” to “no changes,” to “mildly negative changes,” to “moderately negative changes,” to “mostly negative changes.”

TABLE 1
Subjective Vaginal Health Questionnaire Questions
	Question	Select Response
1	How many children have	Natural Delivery?
	you had by:	Cesarean Section?
2	How many vaginal infec-
	tions have you had in the
	last 6 months?
3	How many urinary tract
	infections have you had in
	the last 6 months?
4	What is the severity of any	a) No Leakage (never use protection)?
	urinary incontinence that	b) Mild Leakage (no protection
	you experience?	necessary)?
		c) Moderate Leakage (occasionally wear
		protection)?
		d) Moderately Severe Leakage
		(regularly wear protection)?
		e) Severe Leakage (must change
		protection more than 2 times per day)?
5	If you experience any	a) When laughing, coughing, straining
	amount of urinary inconti-	or physically active?
	nence, when does it occur?	b) Leakage is uncontrollable and is
		preceded by a strong urge or need to
		urinate.
		c) Leakage occurs without apparent
		cause.
6	What is the number that	Scale of 1 to 7 with 1 representing no
	most closely represents	vaginal dryness and 7 representing
	your degree of vaginal	extreme vaginal dryness.
	dryness?
7	What is the number that	Scale of 1 to 7 with 1 representing no
	most closely represents	vaginal itching or irritation and 7 repre-
	your degree of vaginal	senting extreme vaginal itching or
	itching or irritation?	irritation.
8	Are you taking any pro-
	ducts to assist with vaginal
	dryness, irritation or
	itching?
9	What is your overall	No Problems.
	vaginal health.	Mild Problems.
		Moderate Problems.
		Moderately Severe Problems.
		Severe Problems.
10	What is the occurrence and	a) None
	frequency of any type of	b) Rare (less than 1 per month)
	sexual activity?	c) Infrequent (1-3 times per month)
		d) Regular (1-3 times per week)
		e) Frequent (more than 3 times per
		week)
11	What is the occurrence of	a) None
	orgasm (by any means)	b) Rare (less than 1 per month)
	with sexual activity?	c) Infrequent (1-3 times per month)
		d) Regular (1-3 times per week)
		e) Frequent (more than 3 times per
		week)
12	Has anything happened in	(e.g., change in health status or change
	your personal life to de-	in relationships, etc.)
	crease your interest in
	sexual activity?

Claims

1. A method for improving or maintaining urogenital health comprising administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

2. A method of claim 1 wherein the patient is a postmenopausal woman.

3. A method of claim 1 wherein the estrogen agonist/antagonist is a compound of formula (I):

4. A method of claim 1 wherein the estrogen agonist/antagonist is a compound of formula (IA)

5. A method of claim 1 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

6. A method of claim 5 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

7. A method of claim 1 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

8. A method of lowering vaginal pH, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

9. A method of claim 8 wherein the patient is a postmenopausal woman.

10. A method of claim 8 wherein the estrogen agonist/antagonist is a compound of formula (I):

11. A method of claim 8 wherein the estrogen agonist/antagonist is a compound of formula (IA)

12. A method of claim 8 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

13. A method of claim 12 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

14. A method of claim 8 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

15. A method of treating an urinary tract infection, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

16. A method of claim 15 wherein the patient is a postmenopausal woman.

17. A method of claim 15 wherein the estrogen agonist/antagonist is a compound of formula (I):

18. A method of claim 15 wherein the estrogen agonist/antagonist is a compound of formula (IA)

19. A method of claim 15 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

20. A method of claim 19 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

21. A method of claim 15 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

22. A method of treating vaginal dryness, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

23. A method of claim 22 wherein the patient is a postmenopausal woman.

24. A method of claim 22 wherein the estrogen agonist/antagonist is a compound of formula (I):

25. A method of claim 22 wherein the estrogen agonist/antagonist is a compound of formula (IA)

26. A method of claim 22 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

27. A method of claim 26 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

28. A method of claim 22 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

29. A method of treating vaginal itching, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

30. A method of claim 29 wherein the patient is a postmenopausal woman.

31. A method of claim 29 wherein the estrogen agonist/antagonist is a compound of formula (I):

32. A method of claim 29 wherein the estrogen agonist/antagonist is a compound of formula (IA)

33. A method of claim 29 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

34. A method of claim 33 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

35. A method of claim 29 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

36. A method of treating undesired vaginal spasms, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

37. A method of claim 36 wherein the patient is a postmenopausal woman.

38. A method of claim 36 wherein the estrogen agonist/antagonist is a compound of formula (I):

39. A method of claim 36 wherein the estrogen agonist/antagonist is a compound of formula (IA)

40. A method of claim 36 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

41. A method of claim 40 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

42. A method of claim 36 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

44. A method of treating vaginitis, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

45. A method of claim 44 wherein the patient is a postmenopausal woman.

46. A method of claim 44 wherein the estrogen agonist/antagonist is a compound of formula (I):

47. A method of claim 44 wherein the estrogen agonist/antagonist is a compound of formula (IA)

48. A method of claim 44 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

49. A method of claim 48 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

50. A method of claim 44 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

51. A method of treating a vaginal yeast or bacterial infection, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

52. A method of claim 51 wherein the patient is a postmenopausal woman.

53. A method of claim 51 wherein the estrogen agonist/antagonist is a compound of formula (I):

54. A method of claim 51 wherein the estrogen agonist/antagonist is a compound of formula (IA)

55. A method of claim 51 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

56. A method of claim 55 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

57. A method of claim 51 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

58. A method of treating vulvar atrophy, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

59. A method of claim 58 wherein the patient is a postmenopausal woman.

60. A method of claim 58 wherein the estrogen agonist/antagonist is a compound of formula (I):

61. A method of claim 58 wherein the estrogen agonist/antagonist is a compound of formula (IA)

62. A method of claim 58 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

63. A method of claim 62 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

64. A method of claim 58 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

65. A method of treating urethrocele, cystocele, rectocele or enterocele prolapse, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

66. A method of claim 65 wherein the patient is a postmenopausal woman.

67. A method of claim 65 wherein the estrogen agonist/antagonist is a compound of formula (I):

68. A method of claim 1 wherein the estrogen agonist/antagonist is a compound of formula (IA)

69. A method of claim 65 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

70. A method of claim 69 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

71. A method of claim 65 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

72. A method of treating urinary or anal incontinence, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

73. A method of claim 72 wherein the patient is a postmenopausal woman.

74. A method of claim 72 wherein the estrogen agonist/antagonist is a compound of formula (I):

75. A method of claim 72 wherein the estrogen agonist/antagonist is a compound of formula (IA)

76. A method of claim 72 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

77. A method of claim 76 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

78. A method of claim 72 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

79. A method of treating undesired urinary frequency or urgency, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

80. A method of claim 79 wherein the patient is a postmenopausal woman.

81. A method of claim 79 wherein the estrogen agonist/antagonist is a compound of formula (I):

82. A method of claim 79 wherein the estrogen agonist/antagonist is a compound of formula (IA)

83. A method of claim 79 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

84. A method of claim 83 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

85. A method of claim 79 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

86. A method of increasing the frequency or intensity of orgasms in a female patient, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an estrogen agonist/antagonist.

87. A method of claim 86 wherein the patient is a postmenopausal woman.

88. A method of claim 86 wherein the estrogen agonist/antagonist is a compound of formula (I):

89. A method of claim 86 wherein the estrogen agonist/antagonist is a compound of formula (IA)

90. A method of claim 86 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

91. A method of claim 90 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

92. A method of claim 86 wherein the estrogen agonist/antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

93. A kit for use by a consumer to improve or maintain urogenital health comprising: (a) a pharmaceutical composition comprising an estrogen agonist/antagonist and a pharmaceutically acceptable carrier, vehicle or diluent; and (b) instructions describing a method of using the pharmaceutical composition to improve or maintain urogenital health; lower vaginal pH; treat urinary tract infections; treat vaginal dryness; treat vaginal itching; treat undesired vaginal spasms; treat vaginitis; treat vaginal yeast or bacterial infections; treat vulvar atrophy; treat cystocele, urethocele, rectocele or enterocele prolapse; treat urinary or anal incontinence; treat undesired urinary frequency or urgency; or increase the frequency or intensity of orgasms.

94. A kit of claim 93 wherein the estrogen agonist/antagonist is a compound of formula (I):

95. A kit of claim 93 wherein the estrogen agonist/antagonist is a compound of formula (IA):

96. A kit of claim 93 wherein the estrogen agonist/antagonist is (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

97. A kit of claim 96 wherein the estrogen agonist/antagonist is in the form of a D-tartrate salt.

98. A kit of claim 93 wherein the estrogen agonist/antagonist is selected from selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:

99. A method for assessing vaginal health in a patient, the method comprising: a) conducting a gynecological examination; b) measuring the pH of the vagina; c) determining the vaginal cell maturation index; d) determining vaginal prolapse; e) administering a questionnaire to the patient; and f) measuring plasma hormone levels, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.

100. A method of claim 99 wherein the gynecological examination comprises an internal evaluation of the vagina in which the condition of the vagina is characterized by indicating the condition of the vagina on a continuum using I and III below as endpoints and II as the midpoint of the continuum: I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry; II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length.

101. A method of claim 100 wherein the gynecological exam further comprises an assessment of the quantity of pubic hair and the thickness of the vulva.

102. A method of claim 99 wherein the plasma hormone levels that are measured include estradiol, luteinizing hormone, follicle-stimulating hormone, testosterone and androstenedione.

103. A method of claim 99 wherein vaginal prolapse is determined by grading the prolapse using the following scale:

104. A method of claim 99 wherein the questionnaire comprises questions relating to: 1) the number of vaginal infections; 2) the number of urinary infections; 3) the amount of urinary leakage; 4) the degree of vaginal dryness; 5) the degree of vaginal itching; and 6) a subjective assessment of overall vaginal health by the patient.

105. A method for assessing vaginal health in a patient, the method comprising: a) conducting a gynecological examination that comprises an internal evaluation of the vagina in which the condition of the vagina is characterized by indicating the condition of the vagina on a continuum using I and III below as endpoints and II as the midpoint of the continuum: I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry; II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length; and assessing the quantity of pubic hair and the thickness of the vulva; b) measuring the pH of the vagina; c) determining the vaginal cell maturation index; d) determining vaginal prolapse using the following scale: 7Grade 0normal position inside the mid-vaginal axis for anterior posteriorwall prolapse and above the ischial spines for cervical or vaginalcuff. By definition, the most apical point is −3 cm superior to thehymen.Grade 1if the prolapse crosses the respective thresholds and descendshalfway to the hymenGrade 2decent to the hymenGrade 3decent 2 cm beyond the hymenGrade 4maximum possible descent for each site. A complete eversion isabout 5 cm beyond hymen.e) administering a questionnaire to the patient, the questionnaire comprising questions relating to: 1) the number of vaginal infections in a specified time period; 2) the number of urinary infections in a specified time period; 3) the amount of urinary leakage in a specified time period; 4) the degree of vaginal dryness in a specified time period; 5) the degree of vaginal itching; and 6) a subjective assessment of overall vaginal health by the patient; and f) measuring plasma levels of estradiol, luteinizing hormone, follicle-stimulating hormone, testosterone and androstenedione, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.